Navigation Links
Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Date:2/26/2008

PRINCETON, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the completion of recruitment in the company's multi-center Phase 2a clinical study of PS433540 (DARA), the company's lead internal product candidate. The objective of the Phase 2a randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of 200 and 500 mg of PS433540 in subjects with Stage I and Stage II hypertension.

"We have made good progress advancing DARA's clinical development. Not only did we initiate this Phase 2a study approximately six months ahead of our original clinical development timeline, but we have now completed enrollment in the study with the expectation of reporting results in the second quarter of 2008," said Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "As this is the first PS433540 study to include hypertensive patients, we are pleased to have the opportunity to demonstrate that DARA can effectively lower blood pressure in this patient population."

Results from Phase 1 studies of PS433540 in normal subjects have indicated that the compound was well tolerated at all doses up to and including 1,000 mg a day for 14 days. Several studies including the multiple ascending dose (MAD) and angiotensin II challenge studies have shown that PS433540 appears to have a pharmacokinetic profile consistent with once-daily oral administration. In the angiotensin challenge study, 250 and 500 mg of PS433540 fully blocked the increase in blood pressure induced by administration of angiotensin II (AII) to healthy volunteers at least as well as 300 mg of irbesartan, the t
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
9. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired by ... months and the 3 rd quarter sales ended September ... was $448,000 for the nine months ended September 2014 and ... though our 3 rd quarter is usually a seasonable ... from July into September for many countries worldwide, we are ...
(Date:11/21/2014)... COLLEGE PARK, Md. , Nov. 21, 2014 /PRNewswire-USNewswire/ ... Engineering today will host the ceremonial groundbreaking of the ... Maryland, College Park. The new building will cultivate transformative ... human health.  Taking place at 10:00 a.m. ... building in the Paint Branch Parking Lot, adjacent to ...
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
Breaking Medicine Technology:CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the ... announced that Mr. Ofir Paz, InspireMD,s co-founder and chief ... will participate in the Benchmark Company, LLC One-on-One Investor ... Hotel, 424 East Wisconsin Ave., Milwaukee, Wis. The conference ...
... Axcan Intermediate Holdings Inc. announces that it ... the recently completed combination of two specialty pharma companies ... also has a new corporate logo and website (please ... "Our new name, Aptalis, is intended to capture the ...
Cached Medicine Technology:InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 2InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 3The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 2The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 3
(Date:11/22/2014)... (PRWEB) November 22, 2014 Sandbridge ... equity investments in the consumer brand sector, acquired ... investment will be used to help fund BackJoy’s ... pipeline rollout, particularly its proprietary apparel and footwear ... join BackJoy’s Board of Directors. , BackJoy is ...
(Date:11/22/2014)... Wright & Schulte LLC reports that ... have been scheduled between October 2016 and April 2017 ... U.S. District Judge Matthew F. Kennelly, who is overseeing ... (CMO) on November 6, 2014 that outlined the trial ... documents and other activities in preparation for the bellwether ...
(Date:11/22/2014)... Nov. 21, 2014 (HealthDay News) -- Those air-blown hand ... than conventional paper towels, a new study suggests. ... the hands of volunteers in order to simulate poorly ... high-powered "jet-air" dryers or paper towels to dry their ... found higher amounts of germs around both types of ...
(Date:11/21/2014)... 21, 2014 CRN International, the radio ... industry sales professional to its award-winning team. , Leslie ... of leadership and sales experience to CRN. She will ... title of Director of Strategy and Development, reporting to ... , Heinemann will handle a wide range of territories ...
(Date:11/21/2014)... -- The cost of diabetes care in the United ... to more than $322 billion annually, a new report ... with prediabetes care, which have risen 74 percent, and ... added. In 2012, excess medical costs and lost ... every American. That total includes $244 billion in medical ...
Breaking Medicine News(10 mins):Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2
... lives in a competitive world, according to a recent ... educational achievements are concerned, // there is not much ... with a normal birth weight. Earlier research suggested premature ... and academic achievement. ,The researchers studied ...
... person was used as a basis to judge the safety ... published in the Journal of the American Medical Association. //The ... of their Indian and White compatriots, where HIV and hepatitis ... to have been implemented by the South African National Blood ...
... increased incidence of kidney failure following use of the ... reconsidering the use of the drug in heart surgery ... excessive bleeding in patients undergoing cardiac surgery. ... that Trasylol injected patients were twice as likely to ...
... and Melinda Gates, scheduled to commence in June, has ... foundation Release. Dr Tadataka Yamada, // Chair of Research ... ,Yamada’s key portfolio will focus on driving the ... availability of drugs to fight diseases such as Aids, ...
... Research, Sydney have expressed hope over their newly developed ... //It is also claimed to improve the clinical outcome ... psoriasis and post transplant recipients. ,The unique ... and promising results have been obtained. It has been ...
... reportedly being prohibited on the grounds of unscientific fears, according ... The British Medical Journal had already published a report which ... risk //of heart and lung diseases. Most smokers consider the ... an end to smoking altogether. ,The Utah ...
Cached Medicine News:Health News:Safety Of Heart Drug Questioned 2
Stryker Endoscopy offers a wide variety of small-joint arthroscopes that produce a brilliant high-resolution image without sacrificing Stryker's ultra-high tip durability....
... offers new WHITESTAR Technology, which transforms traditional ... dramatically reduces the amount of phaco energy ... full ultrasound cutting efficiency. Surgeons ... safely and efficiently to the phaco tip, ...
... Vitrax features a low molecular ... protection and viscosity you need ... phaco and small-incision surgery. The ... anterior chamber depth for safe, ...
The New Digital Recording System From Luxtec,The new MicroLux Digital Video Recorder gives you an entirely new way to visualize, edit, share and store your surgical cases....
Medicine Products: